# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Daxor (NASDAQ:DXR) with a Buy and raises the price target from $24.5 to $24.75.
The SBIR Matching Fund Award Will Drive Our Innovation, Commercialization Efforts, and Job CreationOak Ridge, TN, Sept. 05, 202...
Dear Valued Shareholders,I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting...
The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)Oak Ridge, TN, July 24, 2024 (GLO...
Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market PenetrationOak Ridge, TN, July 11, 2024 (GLOBE NEW...